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U lcerative colitis is an inflammatory bowel disease that causes inflammation in the digestive tract.  
As the name “ulcerative colitis” implies,  it has long 
been believed that the inflammatory response is local-
ized in the large intestine.  However,  studies conducted 
over the last 20 years have led to advances in our under-
standing of the extent of the disease.  Macroscopic and 
microscopic involvement of the stomach and duode-
num in ulcerative colitis patients has been reported by 
several research groups [1-7] as “gastroduodenitis asso-
ciated with ulcerative colitis,” “ulcerative gastroduode-
nal lesions,” or “ulcerative colitis-associated upper gas-
trointestinal inflammation.” These lesions are reportedly 
observed as friable mucosa,  granular mucosa,  or mul-
tiple aphthae during esophagogastroduodenoscopy [7].
Due to the increasing frequency of ulcerative colitis 
in developed countries since the mid-20th century,  
ulcerative colitis patients have been treated at various 
institutions ranging from tertiary care centers and com-
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To analyze the clinical characteristics of patients with ulcerative colitis who have upper gastrointestinal lesions,  
we retrospectively reviewed the data of 216 patients with ulcerative colitis who underwent esophagogastroduo-
denoscopy at our institute in April 2008-March 2016.  We investigated the endoscopic features and compared 
the clinical characteristics between the patients with and without upper gastrointestinal lesions.  Forty-two 
patients (19.4%) had upper gastrointestinal lesions,  including multiple erosions (n = 18),  bamboo joint-like 
appearance (n = 17),  mucosa with white spots (n = 4),  friable mucosa (n = 2),  ulcer (n = 1),  and purulent depos-
its within the mucosa (n = 1) in the stomach and/or duodenum.  Compared to the patients without upper gas-
trointestinal lesions,  those with upper gastrointestinal lesions showed significantly more frequent extraintesti-
nal manifestations (19.0% vs. 8.0%,  p< 0.05) and a significant history of colectomy (33.3% vs. 12.1%,  p< 0.01).  
There were no significant differences with regard to the sex ratio,  age at esophagogastroduodenoscopy,  gastro-
intestinal symptoms,  time since the diagnosis of ulcerative colitis,  type of colitis at the initial diagnosis of 
ulcerative colitis,  or gastric atrophy between the groups.  In conclusion,  gastroduodenal lesions were identified 
in 19.4% of the patients with ulcerative colitis.  Esophagogastroduodenoscopy is particularly recommended for 
ulcerative colitis patients who show extraintestinal manifestations and for those who have undergone a colec-
tomy.
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munity hospitals to clinics.  One of the concerns in 
treating ulcerative colitis is that the upper gastrointesti-
nal involvement may be overlooked because of the lack 
of recognition of the gastroduodenal lesions by the 
attending physician.  In addition,  since the clinical 
backgrounds of patients with ulcerative colitis-associ-
ated upper gastrointestinal inflammation have not been 
fully revealed,  no criteria have been established to indi-
cate which patients should undergo esophagogastrodu-
odenoscopy.
Patients with ulcerative colitis-associated upper gas-
trointestinal inflammation may require specific treat-
ment for the gastroduodenal lesions.  Hence,  recogni-
tion and detection of the upper gastrointestinal lesions 
are important.  Here we describe 2 cases of ulcerative 
colitis and summarize the results of our investigation of 
the prevalence of upper gastrointestinal involvement 
detected by esophagogastroduodenoscopy.  We also 
analyzed the macroscopic and microscopic features of 
the upper gastrointestinal lesions and patient character-
istics.
Methods
A database search performed at the Department of 
Gastroenterology and Hepatology of our institute iden-
tified 404 patients with ulcerative colitis who were 
treated at our institute between April 2008 and March 
2016.  Among them,  216 patients (53.5%) underwent 
one or more esophagogastroduodenoscopy examina-
tions at our facility.  Therefore,  a total of 216 patients 
were enrolled in this study.
The presence or absence of esophageal,  gastric,  and 
duodenal lesions was macroscopically defined accord-
ing to the results of the esophagogastroduodenoscopy 
examination(s).  Atrophic gastritis,  superficial gastritis,  
verrucous gastritis,  single erosion,  xanthoma,  mucosal 
redness,  candida esophagitis,  esophageal hiatal hernia,  
hyperplastic polyp,  fundic gland polyp,  ulcer scar,  
reflux esophagitis,  ectopic gastric mucosa,  and varices 
were excluded from this study,  since these lesions likely 
occur in no relation with ulcerative colitis.  Verrucous 
gastritis is characterized by mucosal elevation with a 
central depression,  which is usually multiple and 
arranged in chains or clusters in the antrum [8].  For the 
purposes of this paper,  we defined all other lesions as 
upper gastrointestinal lesions because there is no con-
sensus with regard to the definition of upper gastroin-
testinal involvement in ulcerative colitis to date [1].
Based on the presence of the upper gastrointestinal 
lesions,  we divided the 216 patients into 2 groups: the 
patients with positive upper gastrointestinal lesions (the 
Lesion group) and the patients without upper gastroin-
testinal lesions (the No-Lesions group).  We retrospec-
tively reviewed the patients’ endoscopic,  radiological,  
biological,  and pathological examination findings 
obtained from the clinical records of the patients.  The 
patient information in the 2 groups was analyzed and 
compared with regard to sex,  age at the esophagogas-
troduodenoscopy,  time (years) since the diagnosis of 
ulcerative colitis,  the presence or absence of gastroin-
testinal symptoms,  the type of colitis (proctitis,  procto-
sigmoiditis,  left-sided colitis,  and pan-ulcerative coli-
tis) at the initial diagnosis of ulcerative colitis,  the 
presence or absence of extraintestinal manifestations,  
history of surgery for ulcerative colitis,  and gastric 
atrophy.  Two board-certified endoscopists blindly 
assessed the grade of gastric atrophy according to the 
Kimura and Takemoto grading classification [9].  In 
cases of a difference of opinion between 2 endoscopists,  
the grade was determined after discussion.
Pathological features were analyzed when biopsy 
sampling was performed during an esophagogastrodu-
odenoscopy examination.  Lesions with focal enhanced 
gastritis or with aggregates of neutrophils and sloughed 
epithelial cells within a partially ruptured gastrointesti-
nal gland that resemble crypt abscesses were defined as 
ulcerative colitis-associated upper gastrointestinal inflam-
mation [10].
Our statistical analyses of the groups were per-
formed with t-tests,  chi-square tests,  and F-tests using 
JMP 12.0.1 software (SAS,  Cary,  NC,  USA).  P-values 
< 0.05 were considered significant.
The study design was approved by the Ethics Com-
mittee of Okayama University Hospital (No. 1606-018),  
and it adhered to the Declaration of Helsinki.
Results
The patient backgrounds are summarized in Table 1.  
Among the 216 patients who underwent esophagogas-
troduodenoscopy,  upper gastrointestinal lesions were 
identified in 42 (21 men and 21 women) patients 
(19.4%); these patients were classified as the Lesion 
group.  The No-Lesions group was comprised of 174 
patients (94 men,  80 women).
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A comparison of the backgrounds of the patients in 
the 2 groups revealed that extraintestinal manifesta-
tions were observed significantly more frequently in the 
Lesion group (19.0%) compared to the No-Lesions 
group (8.0%,  p < 0.05).  The extraintestinal manifesta-
tions in the Lesion group included arthritis (n = 2),  pri-
mary sclerosing cholangitis (n = 2),  skin lesions (pyo-
derma gangrenosum,  n = 2),  stomatitis (n = 1),  and 
ophthalmia (scleritis,  n = 1).  The extraintestinal mani-
festations in the No-Lesions group were arthritis (n = 9),  
primary sclerosing cholangitis (n = 3),  and skin lesions 
(n = 2; one patient had erythema nodosum and the 
other had both pyoderma gangrenosum and erythema 
nodosum).
In addition,  33.3% of the patients in the Lesion 
group underwent surgery for ulcerative colitis,  at a sig-
nificantly higher rate than that in the No-Lesions group 
(12.1%,  p < 0.01).  There were no significant differences 
between patients in the Lesion and No-Lesions groups 
with regard to sex ratio (males: 50.0% vs. 54.0%),  age 
at esophagogastroduodenoscopy (mean ± SD: 44.3±19.6 
vs. 45.0 ± 15.7 years),  gastrointestinal symptoms (posi-
tive: 40.6% vs. 29.7%),  time since the diagnosis of 
ulcerative colitis (mean ± SD: 9.8±9.9 vs. 8.1±8.1 years),  
type of colitis at the initial diagnosis of ulcerative colitis 
(ratio of pan-ulcerative colitis: 59.5% vs. 49.4%),  and 
gastric atrophy (ratio of C3,  O1,  O2,  and O3: 14.4% 
vs. 13.8%),  respectively.
Macroscopic features of the upper gastrointestinal 
lesions were classified as multiple erosions (n = 18),  
bamboo joint-like appearance (n = 16),  mucosa with 
white spots (n = 4),  friable mucosa (n = 2),  ulcer (n = 1),  
and purulent deposits within the mucosa (n = 1).  The 
typical images of each endoscopic feature are shown in 
Fig. 1.  Table 2 shows the distribution of these features,  
which were observed in the stomach and duodenum.  
No patient had macroscopic lesions in the esophagus.  
One patient had mucosa with white spots along with a 
friable mucosa in the stomach.  In 2 patients,  the mac-
roscopic features changed during the clinical course,  
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Table 1　 Characteristics of the study subjects,  216 ulcerative colitis patients
Lesion group No-Lesions group P-value
Total no. of patients 42 174
　Male 21 94 0.731　
　Female 21 80
Age at the initial EGD (years,  mean ± SD) 44.3±19.6 45.0±15.7 0.815　
Time since the ulcerative colitis diagnosis (years,  mean ± SD) 9.8±9.9 8.1±8.1
Disease extent
　Pancolitis 25 86 0.302　
　Left-sided colitis,  proctosigmoiditis,  and proctitis 17 88
Symptoms
　Present 13 38 0.289　
　Absent 19 90
　Not available 10 46
Extraintestinal manifestations
　Present 8 14 0.046＊
　　Arthritis 2 9
　　Primary sclerosing cholangitis 2 3




History of surgery for ulcerative colitis
　Present 14 21 0.002　
　Absent 28 153
Lesion group: the patients with ulcerative colitis who had upper gastrointestinal lesions.
No-Lesions group: the patients without upper gastrointestinal lesions.  ＊Present vs. absent.
EGD,  esophagogastroduodenoscopy.
and are described below.  All other patients showed a 
single type of macroscopic feature on esophagogastro-
duodenoscopy.  The detailed medication histories of the 
patients in the Lesion group were further investigated,  
revealing that during esophagogastroduodenoscopy,  
nonsteroidal anti-inflammatory drugs (NSAIDs) were 
prescribed for only one patient in whom an ulcer was 
identified.
Biopsy sampling was performed in 18 patients from 
the Lesion group.  Focally enhanced gastritis was iden-
tified in 3 patients; 2 patients had multiple erosions and 
the third patient had bamboo joint-like appearance.  No 
crypt abscess was found in any of the biopsied speci-
mens.  Consequently,  the 3 patients were diagnosed 
with ulcerative colitis-associated upper gastrointestinal 
inflammation [9].
Among the 15 patients without focally enhanced 
gastritis,  nonspecific inflammation within the mucosa 
and submucosa was identified in 11 patients,  and an 
intact gastric mucosa lacking inflammation was 
observed in three patients.  In these three patients,  
biopsy sampling was performed for the bamboo joint-
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Table 2　 Endoscopic features of the upper gastrointestinal lesions
Macroscopic feature No. of patients Stomach Duodenum Stomach and duodenum
Multiple erosions 18 13† 4＊ 1
Bamboo joint-like appearance 17 17＊ 0 0
Mucosa with white spots 4 2 2 1
Friable mucosa 2 1† 0 1
Ulcer 1 0 1 0
Purulent deposits within the mucosa 1 1 0 0
＊Patient 1 presented with multiple erosions in the duodenum during the initial esophagogastroduodenoscopy (EGD),  whereas the second 
EGD showed a bamboo joint-like appearance in the stomach.
†In Patient 2,  gastric lesions were observed as mucosa with white spots at the initial EGD.  The gastric lesions changed into multiple ero-
sions at the second EGD.
A B C
D E F
Fig. 1　 Typical images of macroscopic features of the upper gastrointestinal lesions in patients with ulcerative colitis.  Esophago-
gastroduodenoscopy revealed gastric multiple erosions (A),  a bamboo joint-like appearance in the stomach (B),  duodenal mucosa with 
white spots (C),  duodenal friable mucosa (D),  a duodenal ulcer (E),  and purulent deposits within the gastric mucosa (F).
like appearance.  In the remaining patient,  since the 
samples were obtained from the purulent deposits 
within the mucosa,  the pathologic features could not be 
evaluated due to the small volume of the sample.
Based on the results of an esophagogastroduode-
noscopy examination,  specific treatment for the upper 
gastrointestinal lesions was initiated in 2 patients.  The 
clinical courses of these 2 patients are as follows.
Case 1. A 26-year-old Japanese woman was diag-
nosed with ulcerative colitis.  When she was 27 years 
old,  subtotal proctocolectomy was performed based on 
the deterioration of colitis.  At 32 years of age,  the 
patient underwent esophagogastroduodenoscopy for the 
investigation of epigastralgia,  which revealed multiple 
erosions in the duodenum (Fig. 2A , B).  Powdered 
mesalazine was administered to treat the duodenal 
lesions.  When the patient was 35 years old,  esophago-
gastroduodenoscopy revealed resolution of the duode-
nal erosions (Fig. 2C) and a bamboo joint-like appear-
ance was noted in the gastric cardia (Fig. 2D); this 
appearance had not been identified during the initial 
esophagogastroduodenoscopy.
Case 2. A 14-year-old Japanese boy was diag-
nosed with ulcerative colitis.  He underwent subtotal 
proctocolectomy at 17 years of age.  Esophagogastro-
duodenoscopy performed at 19 years revealed white 
spots in the gastric body (Fig. 3A),  whereas the gastric 
antrum seemed to be intact (Fig. 3B).  The patient was 
treated with powdered mesalazine.  Esophagogastro-
duodenoscopy performed 1 year later showed reddish 
mucosa in the gastric body (Fig. 3C) and multiple ero-
sions in the gastric antrum (Fig. 3D, E).
Discussion
In this study,  42 of the 216 patients (19.4%) who 
underwent esophagogastroduodenoscopy had upper 
gastrointestinal lesions.  Hori et al.  prospectively per-
formed esophagogastroduodenoscopy with biopsies on 
250 patients with ulcerative colitis.  They identified 
ulcerative colitis-associated upper gastrointestinal 
lesions,  which were defined as friable mucosa,  granular 
mucosa,  or multiple aphthae,  in 7.6% of the patients 
[7].  Abnormalities in macroscopic findings have been 
identified in 13-53% of patients with ulcerative colitis 
[7].  Horjus Talabur Horje et al.  reported that no patient 
with ulcerative colitis had upper gastrointestinal lesions,  
whereas macroscopic abnormalities were found in 41% 
of patients with Crohn’s disease during esophagogastro-
duodenoscopy [11].  Such diversity of prevalence likely 
reflects the difference in the definition of upper gastro-
intestinal lesions among the different studies.  Several 
April 2018 UGI Lesions in Ulcerative Colitis 109
A B
C D
Fig. 2　 Endoscopy images of Patient 1.  
Multiple erosions were initially observed in the 
duodenum (A ,B).  After the administration of 
mesalazine powder,  the duodenal erosions 
resolved (C).  A bamboo joint-like appearance 
appeared in the gastric cardia (D).
studies have revealed that a significant proportion of 
patients have macroscopic lesions in the upper gastro-
intestinal tract,  indicating the importance of esophago-
gastroduodenoscopy examinations in the management 
of ulcerative colitis.
As we noted above,  there is no consensus regarding 
the definition of upper gastrointestinal involvement in 
ulcerative colitis to date.  In one prospective study,  
granular,  erythematous mucosa,  erosions,  ulcers,  
nodular lesions and strictures were assessed as upper 
gastrointestinal lesions [11].  In a retrospective study,  
granular mucosa,  erosion,  mucosal friability,  bleeding,  
and ulcers resembling colonic lesions,  were classified as 
upper gastrointestinal lesions [12].  In the majority of 
studies,  as well as in our present investigation,  lesions 
were defined based on the macroscopic features.
Lin et al.  pathologically investigated the upper gas-
trointestinal mucosa and defined ulcerative colitis-asso-
ciated upper gastrointestinal inflammation as lesions 
with focal enhanced gastritis or with aggregates of neu-
trophils and sloughed epithelial cells within a partially 
ruptured gastrointestinal gland,  resembling a crypt 
abscess [10].  This variation in the definitions reflects the 
difficulty of determining the lesions that actually occur 
in relation to ulcerative colitis.  In the present study,  we 
included all mucosal alterations in the upper gastroin-
testinal tract other than atrophic gastritis,  superficial 
gastritis,  verrucous gastritis,  single erosion,  xanthoma,  
mucosal redness,  candida esophagitis,  esophageal hia-
tal hernia,  hyperplastic polyp,  fundic gland polyp,  
ulcer scar,  reflux esophagitis,  ectopic gastric mucosa,  
and varices.  As a result,  we identified multiple ero-
sions,  mucosa with white spots,  friable mucosa,  bam-
boo joint-like appearance,  purulent deposits within the 
mucosa,  and ulcers.  Among these,  ulcer formation 
might occur as an adverse effect due to NSAID use.  In 
contrast,  mucosa with white spots and friable mucosa 
have been reported as findings specific to ulcerative 
colitis [7].  Multiple erosions are also reportedly indica-
tive lesions of upper gastrointestinal involvement with 
ulcerative colitis,  provided other disorders such as viral 
infections,  collagen,  allergic,  autoimmune,  and Crohn’s 
disease are excluded [7].  The significance of purulent 
deposits,  which we observed in one patient,  remains 
unknown,  since the pathological analysis of the biop-
sied specimen was not possible due to the small sample 
size.
The bamboo joint-like appearance of the gastric 
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Fig. 3　 Endoscopy images of Patient 2.  White spots were observed in the gastric body (A),  whereas the gastric antrum was intact (B).  
The patient was treated with powdered mesalazine.  The second esophagogastroduodenoscopy revealed reddish mucosa in the gastric 
body (C) and multiple erosions in the antrum (D ,E).
mucosa (i.e.,  swollen longitudinal folds transversed by 
erosive fissures or linear furrows that are most fre-
quently found at the gastric body and cardia) is a typical 
manifestation of Crohn’s disease.  It is well known that 
44-65% of patients with Crohn’s disease show a bamboo 
joint-like appearance of the gastric mucosa [13 , 14].  
Recent reports on endoscopic gastroduodenal findings 
in patients with inflammatory bowel disease revealed 
that patients with ulcerative colitis have this feature 
[11 , 12 , 14].  In the present study,  the bamboo joint-like 
appearance was found in 17 of the 216 patients (7.9%).  
Our finding reinforces the notion that the bamboo 
joint-like appearance of the gastric mucosa can be seen 
in patients with ulcerative colitis as well as in those with 
Crohn’s disease.
In our study,  extraintestinal manifestations were 
more frequently observed in the patients with positive 
upper gastrointestinal lesions.  Moreover,  the Lesion 
group included a higher percentage of patients who had 
undergone colectomy.  The reported risks for develop-
ing upper gastrointestinal lesions include more exten-
sive colitis,  a lower dose of prednisolone,  the presence 
of pouchitis,  post-colectomy status,  and a longer post-
operative period [7 , 11 , 16-22].  Although the precise 
mechanisms underlying the upper gastrointestinal 
lesions are unclear,  several authors have speculated that 
immune response to the as-yet unidentified factors 
associated with ulcerative colitis may also be the cause,  
since patient characteristics that are suggestive of severe 
inflammation are reportedly related to gastroduodenal 
manifestations [1 , 2 , 5 , 23].
In the present study,  the extent of colitis was not a 
significant factor in the development of upper gastroin-
testinal lesions.  However,  the type of colitis was defined 
at the initial diagnosis of ulcerative colitis,  and infor-
mation regarding the disease extent at the time of 
esophagogastroduodenoscopy examination was not 
available,  since esophagogastroduodenoscopy and colo-
noscopy were performed at different time points in 
most of the patients.  Although an evaluation of disease 
extent and activity may be useful to predict the presence 
of upper gastrointestinal lesions,  further studies are 
required in this regard.  Based on the results of the pres-
ent study,  we speculate that esophagogastroduodenos-
copy is particularly recommended for patients with 
ulcerative colitis who show extraintestinal manifesta-
tions and in those who have undergone colectomy.  
Among the 188 patients with ulcerative colitis who had 
never undergone esophagogastroduodenoscopy,  21 
(11.2%) were in post-colectomy status.  We thus intend 
to perform esophagogastroduodenoscopies in this 
patient population.
Pathologically,  focally enhanced gastritis was identi-
fied in 3 patients.  This feature represents intense focal 
inflammation characterized by localized collections of 
lymphocytes,  neutrophils,  and macrophages in the 
lamina propria [10].  Focally enhanced gastritis was 
originally described in patients with Crohn’s disease by 
Oberhuber et al.  in 1997 [24].  To date,  this is the most 
common upper gastrointestinal inflammation in ulcer-
ative colitis.  Lin et al.  reported that 29% of patients with 
ulcerative colitis had focally enhanced gastritis,  whereas 
9% of control patients had this feature.  A 12-29% prev-
alence of focally enhanced gastritis was reported in 
ulcerative colitis [10,  25-27].  Crypt abscess,  a patho-
logical hallmark of the large intestine in ulcerative coli-
tis,  can be identified in the upper gastrointestinal tract 
as well.  Hori et al.  reported that crypt abscesses were 
observed significantly more frequently in the gastrodu-
odenal mucosa of patients with ulcerative colitis than in 
controls [7].  However,  none of the patients in the pres-
ent study had a crypt abscess.  Nonspecific inflamma-
tion within the mucosa and submucosa was also identi-
fied in 11 patients without focally enhanced gastritis.  
This observation is consistent with a report that non-
specific inflammation in the upper gastrointestinal tract 
is observed in 60-90% of patients with ulcerative colitis 
[5].
Upper gastrointestinal lesions in ulcerative colitis 
may be treated with steroids,  leukocytapheresis,  and/or 
peroral mesalazine powder [12].  Immunosuppression 
with cyclosporine,  tacrolimus,  or infliximab is likely to 
be the treatment of choice for upper gastrointestinal 
inflammation as well.  In the present study,  mesalazine 
powder was administered to 2 patients,  and the macro-
scopic features of the upper gastrointestinal lesions were 
found to have changed after the administration of this 
drug.  One possible explanation is that mesalazine pow-
der contributed to the altered macroscopic features.  
Another hypothesis is that the patients’ morphology 
simply changed with time.  Since the change in mor-
phology was observed in only 2 patients,  further stud-
ies are required to determine the exact factor(s) that 
affect the morphology.
Our study has several limitations.  It was a retro-
spective analysis.  Since esophagogastroduodenoscopy 
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was indicated in each patient by his or her attending 
physician,  the timing of the examination during the 
course of ulcerative colitis varied.  At our institution,  
we perform esophagogastroduodenoscopy for almost all 
patients with ulcerative colitis who have symptoms 
related to the upper gastrointestinal tract.  Moreover,  
we usually recommend that patients with ulcerative 
colitis undergo esophagogastroduodenoscopy at least 
once.  However,  188 of the 404 patients with ulcerative 
colitis (46.5%) in our study had never undergone an 
esophagogastroduodenoscopy examination.  It is likely 
that the number of patients who underwent esophago-
gastroduodenoscopy and the reason for esophagogas-
troduodenoscopy might have affected the prevalence of 
the upper gastrointestinal lesions.
Second,  our institute is a tertiary care center,  where 
patients with ulcerative colitis who show relatively 
severe inflammation are referred from primary and sec-
ondary care centers.  Such a composition of patients 
might affect the prevalence of upper gastrointestinal 
lesions.  Third,  although Helicobacter pylori is a well-
known pathogen that causes various mucosal alterations 
in the stomach,  the status of infection was not exam-
ined in this study,  and only the presence of atrophic 
gastritis was endoscopically evaluated.  Therefore,  the 
influence of H. pylori on the gastroduodenal features 
could not be precisely assessed.  It is noteworthy that 
several studies reported a negative association between 
H. pylori infection and ulcerative colitis [28-30].  
Further studies with detailed information on H. pylori 
infection status are required to determine the roles of 
this organism in the pathogenesis,  disease extent,  
severity,  and upper gastrointestinal involvement of 
ulcerative colitis.
In conclusion,  macroscopic lesions on esophago-
gastroduodenoscopy were observed in 19.4% of the 
patients with ulcerative colitis.  Esophagogastroduo-
denoscopy is particularly recommended for patients 
with ulcerative colitis who show extraintestinal mani-
festations and for patients who have undergone a colec-
tomy.
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